

Yiping Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10006981/publications.pdf>

Version: 2024-02-01

97
papers

7,526
citations

186209

28
h-index

58549

82
g-index

113
all docs

113
docs citations

113
times ranked

7352
citing authors

#	ARTICLE	IF	CITATIONS
1	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2011, 12, 735-742.	5.1	3,758
2	Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 832-842.	5.1	350
3	Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 916.	3.8	310
4	Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 305-314.	5.2	277
5	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 867-875.	0.5	260
6	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). <i>British Journal of Cancer</i> , 2018, 118, 654-661.	2.9	192
7	Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 437-446.	5.2	192
8	Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 8, 1132-1143.	3.2	169
9	Pyrotinib in <i>HER2</i> -Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 2753-2761.	0.8	123
10	Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 544-557.	0.5	114
11	Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 45-53.	5.2	105
12	A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance. <i>Cancer Medicine</i> , 2017, 6, 154-162.	1.3	82
13	Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. <i>Journal of Translational Medicine</i> , 2016, 14, 188.	1.8	72
14	Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 829-839.	5.2	66
15	Salvage treatment with apatinib for advanced non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1821-1825.	1.0	59
16	Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2). <i>Nature Communications</i> , 2022, 13, 857.	5.8	50
17	Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma. <i>Lung Cancer</i> , 2016, 99, 166-171.	0.9	49
18	A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2014, 86, 207-212.	0.9	47

#	ARTICLE	IF	CITATIONS
19	Brain Metastases from Esophageal Cancer: Clinical Review of 26 Cases. <i>World Neurosurgery</i> , 2014, 81, 131-135.	0.7	46
20	Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing) Tj ETQq0 0 0 rgBT /Overlock 10 Tf lung cancer. <i>Investigational New Drugs</i> , 2018, 36, 315-322.	1.2	42
21	A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7548-7548.	0.8	42
22	Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). <i>Lung Cancer</i> , 2021, 152, 7-14.	0.9	40
23	Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with <i>EGFR</i> mutation-positive advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7520-7520.	0.8	40
24	Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2018, 118, 57-61.	0.9	39
25	Patients with <sc>ROS</sc>1 rearrangementâ€positive nonâ€smallâ€cell lung cancer benefit from pemetrexedâ€based chemotherapy. <i>Cancer Medicine</i> , 2016, 5, 2688-2693.	1.3	35
26	China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	34
27	Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma. <i>Lung Cancer</i> , 2016, 101, 16-21.	0.9	32
28	Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing. <i>Oncotarget</i> , 2016, 7, 61755-61763.	0.8	29
29	Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated NSCLC patients who develop brain metastasis. <i>Archives of Medical Science</i> , 2018, 14, 1298-1307.	0.4	28
30	Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 989-999.	1.3	28
31	On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial. <i>Molecular Cancer</i> , 2022, 21, 4.	7.9	28
32	Mutation and prognostic analyses of <sc>PIK</sc>3<sc>CA</sc> in patients with completely resected lung adenocarcinoma. <i>Cancer Medicine</i> , 2016, 5, 2694-2700.	1.3	26
33	Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1403-1414.	0.5	26
34	Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial. <i>BMC Medicine</i> , 2022, 20, 42.	2.3	26
35	ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4000-4000.	0.8	25
36	ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases. <i>Journal of Thoracic Disease</i> , 2017, 9, 3919-3926.	0.6	24

#	ARTICLE	IF	CITATIONS
37	<p>The efficacy and safety of anlotinib treatment for advanced lung cancer</p>. OncoTargets and Therapy, 2019, Volume 12, 6549-6554.	1.0	24
38	Liquid biopsies using pleural effusion-derived exosomal DNA in advanced lung adenocarcinoma. Translational Lung Cancer Research, 2019, 8, 392-400.	1.3	24
39	Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing. Journal of Thoracic Oncology, 2021, 16, 827-839.	0.5	24
40	Pyrotinib in Patients with HER2-Amplified Advanced Nonâ€“Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial. Clinical Cancer Research, 2022, 28, 461-467.	3.2	24
41	Platinumâ€“based chemotherapy plus cetuximab firstâ€“line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an openâ€“label, singleâ€“arm, multicenter trial. Head and Neck, 2015, 37, 1081-1087.	0.9	22
42	De Novo MET Amplification in Chinese Patients With Nonâ€“Small-Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study. Clinical Lung Cancer, 2019, 20, e171-e176.	1.1	22
43	<i>HER2</i> mutations in Chinese patients with non-small cell lung cancer. Oncotarget, 2016, 7, 78152-78158.	0.8	22
44	Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases. Journal of Clinical Neuroscience, 2014, 21, 591-595.	0.8	21
45	First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.. Journal of Clinical Oncology, 2021, 39, 4049-4049.	0.8	19
46	Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). Lung Cancer, 2021, 154, 176-185.	0.9	18
47	The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study. Cancer Immunology, Immunotherapy, 2022, 71, 1693-1703.	2.0	18
48	Chemotherapy and prognosis in advanced thymic carcinoma patients. Clinics, 2015, 70, 775-780.	0.6	16
49	Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis. Cell Death and Disease, 2021, 12, 106.	2.7	16
50	Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as firstâ€“line treatment for Chinese patients with unresectable, metastatic, or recurrent nonâ€“squamous nonâ€“smallâ€“cell lung cancer: A multicenter, randomized, doubleâ€“blinded, phase III trial. Cancer Communications, 2021, 41, 889-903.	3.7	16
51	Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation.. Journal of Clinical Oncology, 2019, 37, 9089-9089.	0.8	16
52	Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients. Lung Cancer, 2019, 136, 23-29.	0.9	15
53	Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 572853.	1.3	15
54	Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma. OncoTargets and Therapy, 2014, 7, 1875.	1.0	14

#	ARTICLE	IF	CITATIONS
55	Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients. <i>Cancer Biology and Therapy</i> , 2017, 18, 883-887.	1.5	14
56	MET Gene Amplification and Overexpression in Chinese Non-Small-Cell Lung Cancer Patients Without EGFR Mutations. <i>Clinical Lung Cancer</i> , 2017, 18, 213-219.e2.	1.1	13
57	Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer. <i>Translational Oncology</i> , 2020, 13, 100784.	1.7	13
58	Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer. <i>Archives of Medical Science</i> , 2015, 1, 164-168.	0.4	13
59	PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 1385-1392.	0.6	12
60	A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA study. <i>Lung Cancer</i> , 2020, 146, 252-262.	0.9	12
61	Safety and activity of WX-0593 (Iruplinkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 25.	7.1	12
62	Treatment and prognosis of type B2 thymoma. <i>World Journal of Surgical Oncology</i> , 2014, 12, 291.	0.8	11
63	Primary neuroendocrine tumors of the thymus: Clinical review of 22 cases. <i>Oncology Letters</i> , 2014, 8, 2125-2129.	0.8	10
64	Efficacy and safety of aflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study. <i>Journal of Clinical Oncology</i> , 2020, 38, 9602-9602.	0.8	10
65	Rare frequency of gene variation and survival analysis in thymic epithelial tumors. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6337-6342.	1.0	9
66	Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 165, 71-81.	0.9	9
67	Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor. <i>OncoTargets and Therapy</i> , 2016, 9, 211.	1.0	7
68	Treatment and Prognosis of Solid and Cystic Brain Metastases in Patients with Non-Small-Cell Lung Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 6309-6317.	0.9	7
69	Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy. <i>Chinese Medical Journal</i> , 2014, 127, 266-71.	0.9	7
70	Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial. <i>BMC Medicine</i> , 2022, 20, 154.	2.3	7
71	Docetaxel-based chemotherapy as second-line regimen for advanced thymic carcinoma. <i>Thoracic Cancer</i> , 2014, 5, 169-173.	0.8	6
72	CMAB009 plus irinotecan versus irinotecan only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial. <i>Cancer Communications</i> , 2019, 39, 1-13.	3.7	6

#	ARTICLE	IF	CITATIONS
73	Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study. <i>Journal of Thoracic Disease</i> , 2020, 12, 639-650.	0.6	6
74	A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China. <i>Targeted Oncology</i> , 2022, 17, 1-13.	1.7	6
75	Treatment and prognosis after progression in long-term responders to EGFR-tyrosine kinase inhibitor in advanced non-small cell lung cancer. <i>Archives of Medical Science</i> , 2016, 1, 107-111.	0.4	5
76	A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naïve unresectable or metastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 3347-3359.	0.6	5
77	Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study. <i>BMC Pulmonary Medicine</i> , 2022, 22, 179.	0.8	5
78	Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib. <i>Molecular and Clinical Oncology</i> , 2013, 1, 875-878.	0.4	4
79	Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China. <i>Chinese Clinical Oncology</i> , 2020, 9, 68-68.	0.4	4
80	Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 7559-7559.	0.8	4
81	Retreatment with pemetrexed chemotherapy in advanced non-small cell lung cancer patient. <i>Journal of Thoracic Disease</i> , 2014, 6, 856-60.	0.6	4
82	Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients. <i>Journal of Thoracic Disease</i> , 2019, 11, 3712-3720.	0.6	3
83	Clinical efficacy and safety of mecapegligrastim in small cell lung cancer as primary prophylaxis of neutropenia post chemotherapy: a retrospective analysis. <i>Annals of Palliative Medicine</i> , 2021, 10, 7841-7846.	0.5	3
84	Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study. <i>Journal of Clinical Oncology</i> , 2013, 31, e19161-e19161.	0.8	3
85	The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-7.	0.4	3
86	Efficacy and Safety of High-Dose Controlled-Release Oxycodone in the Treatment of Moderate to Severe Pain in Patients with Advanced Cancer: A Retrospective Study. <i>Medical Science Monitor</i> , 2018, 24, 0-0.	0.5	1
87	Pharmacist-Led Management Improves Treatment Adherence and Quality of Life in Opioid-Tolerant Patients With Cancer Pain: A Randomized Controlled Trial. <i>Pain and Therapy</i> , 2022, 11, 241-252.	1.5	1
88	A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2022, 166, 98-106.	0.9	1
89	A phase II trial of ALK/ROS1 tyrosine kinase inhibitor WX-0593 (iruplinalkib) in ALK-positive and crizotinib-resistant advanced non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 9073-9073.	0.8	1
90	Abstract CT505: Phase I study of D-1553 to assess safety and efficacy in patients with non-small cell lung cancer (NSCLC) harboring KRASG12C mutation. <i>Cancer Research</i> , 2022, 82, CT505-CT505.	0.4	1

#	ARTICLE	IF	CITATIONS
91	Progression pattern and post-progression treatment of furmonertinib (AST2818) in EGFR T790M mutation positive NSCLC patients: A post-hoc analysis from a multicenter, single-arm study.. Journal of Clinical Oncology, 2021, 39, e21071-e21071.	0.8	0
92	Randomized phase II study of recombinant human endostatin in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer (NCT00912392).. Journal of Clinical Oncology, 2012, 30, 7091-7091.	0.8	0
93	Epidermal growth factor receptor mutation in small cell lung cancer patients detected by mutant-enriched liquidchip technology from plasma in China.. Journal of Clinical Oncology, 2012, 30, e17512-e17512.	0.8	0
94	A retrospective analysis of the ICOGEN clinical trial demonstrates the utility of VeriStrat to predict outcome in an all Chinese cohort treated with EGFR TKI.. Journal of Clinical Oncology, 2016, 34, e20626-e20626.	0.8	0
95	A phase III trial (ZJBIO009): CMAB009 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type K-ras metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2017, 35, 3513-3513.	0.8	0
96	Distinct resistant mechanism and genomic evolution during TKI treatment in non-small cell lung cancer patients with or without acquired T790M mutation.. Journal of Clinical Oncology, 2019, 37, e20603-e20603.	0.8	0
97	Efficacy and safety of IBI305 compared with bevacizumab in advanced non-squamous NSCLC patients as first-line treatment in a randomized, double-blind, phase III study.. Journal of Clinical Oncology, 2019, 37, 9095-9095.	0.8	0